Standardization and similarity deliberation of Drug-names

Abstract

 In an effort to standardize a drug-code, we carried out a fundamental examination of drug names. We began by itemizing terms according to name (trade-mark) type, and other factors and subdivided them into 23 elemental groups, basing our analysis on each element. Although there is a need to standardize drug names, it was necessary for the names of drugs to be abbreviated for clinical efficiency. It was also assumed that we needed to be careful for similarity of drug names from the viewpoint of risk management and we tried to examine this similarity based on stem words in product names. As a result we decided it was useful to carry out an objective evaluation of degrees of similarity in drug names. For standardization, it became clear that analysis and rearrangement were necessary to provide a method to reach results.